title: Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
abstract: BACKGROUND
  The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial investigates the efficacy and safety of adjuvant exemestane alone and in sequence after tamoxifen in postmenopausal women with hormone-sensitive early breast cancer. As there was a nationwide participation in The Netherlands, we studied the variations in patterns of care in the Comprehensive Cancer Centre Regions (CCCRs) and compliance with national guidelines.
  
  
  METHODS
  Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected.
  
  
  RESULTS
  From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < or =2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001).
  
  
  CONCLUSIONS
  In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement.
authors.affiliation: Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
authors.forename: J G H
authors.initials: JG
authors.lastname: van Nes
authors.forename: C
authors.initials: C
authors.lastname: Seynaeve
authors.forename: E
authors.initials: E
authors.lastname: Maartense
authors.forename: R M H
authors.initials: RM
authors.lastname: Roumen
authors.forename: R S
authors.initials: RS
authors.lastname: de Jong
authors.forename: L V A M
authors.initials: LV
authors.lastname: Beex
authors.forename: W M
authors.initials: WM
authors.lastname: Meershoek-Klein Kranenbarg
authors.forename: H
authors.initials: H
authors.lastname: Putter
authors.forename: J W R
authors.initials: JW
authors.lastname: Nortier
authors.forename: C J H
authors.initials: CJ
authors.lastname: van de Velde
mesh_terms: D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007390:International Agencies; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017698:Postmenopause; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; C056516:exemestane